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Abstract
Background: Pulmonary tuberculosis (TB) is a highly lethal infectious disease and early diagnosis of TB is critical for
the control of disease progression. The objective of this study was to profile a panel of serum microRNAs (miRNAs)
as potential biomarkers for the early diagnosis of pulmonary TB infection.
Methods: Using TaqMan Low-Density Array (TLDA) analysis followed by quantitative reverse transcriptase polymerase
chain reaction (qRT-PCR) validation, expression levels of miRNAs in serum samples from 30 patients with active
tuberculosis and 60 patients with Bordetella pertussis (BP), varicella-zoster virus (VZV) and enterovirus (EV) were analyzed.
Results: The Low-Density Array data showed that 97 miRNAs were differentially expressed in pulmonary TB patient sera
compared with healthy controls (90 up-regulated and 7 down-regulated). Following qRT-PCR confirmation and receiver
operational curve (ROC) analysis, three miRNAs (miR-361-5p, miR-889 and miR-576-3p) were shown to distinguish TB
infected patients from healthy controls and other microbial infections with moderate sensitivity and specificity (area
under curve (AUC) value range, 0.711-0.848). Multiple logistic regression analysis of a combination of these three miRNAs
showed an enhanced ability to discriminate between these two groups with an AUC value of 0.863.
Conclusions: Our study suggests that altered levels of serum miRNAs have great potential to serve as non-invasive
biomarkers for early detection of pulmonary TB infection.
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Background
Pulmonary tuberculosis (TB) caused by Mycobacterium
tuberculosis remains a lethal infectious disease and has
resulted in increased health care costs, especially in deve-
loping countries [1,2]. Early diagnosis of TB infection is
essential for the control of the spread of tuberculosis and
for adequate antimicrobial therapy against mycobacterial
infection. Nevertheless, TB can be a difficult disease to
diagnose. The gold standard of TB diagnostics is confir-
mation with organism growth in selective media, but this
culture in clinical specimens requires long incubation time
(3–12 weeks) for slow growth of mycobacteria [3]. Sputum
smear provides rapid results and is widely used in clinical
laboratories, but this conventional method shows low sen-
sitivity. PCR-based nucleic acid amplification assays and
Immunological tests brought great progress in TB rapid
diagnostics [4-8]. However, endogenous amplification in-
hibition factor of M. tuberculosis or unreliable quality con-
trol resulting in both false positives and negatives have
hampered the clinical use of PCR assays. Immunological
tests are time consuming and require confirmation in lon-
gitudinal analyses and further functional studies. New bio-
markers or methods for TB diagnosis are urgently needed.
Recently, microRNA (miRNA) as a new disease diag-
nosis biomarker has been intensively studied in many
areas, such as various cancers, heart disease, pregnancy,
diabetes, psychosis, and various infectious diseases [9-
15]. Studies have shown that miR-155 and miR-155* in
peripheral blood mononuclear cells (PBMCs) isolated
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from active TB (ATB) patients exhibited characteristic
expression under purified protein derivative (PPD) chal-
lenge [16]. MiRNA expression profiles were different in
PBMCs from patients with active TB, latent TB infection
(LTB), and healthy controls [17]. Differences in miRNA
expression of whole-blood between TB and sarcoidosis
(SARC) were also detected [18]. Accumulating data have
suggested that miRNA could serve as a new potential
diagnostic marker for TB infection. Serum miRNAs are
present in a stable form that is protected from endoge-
nous RNase activity [19]. Their expression level was
consistent among individuals of the same species [19].
Serum, plasma, or other fluid specimens are readily
available and noninvasive, these unique characteristics
make serum miRNAs become useful biomarkers for di-
sease diagnosis. In this study, we identified the serum
miRNAs differentially expressed in patients with active
pulmonary TB and explored the potency of serum
miRNA expression profiles as an early diagnosis bio-
marker for TB infection.
Methods
Sample collection
A total of 155 participants, including 30 patients with
TB infection and 65 healthy subjects were recruited
from four districts in the Jiangsu Province between
December 2009 and August 2010. Among them, twenty
active TB patients and twenty healthy controls were first
recruited in the Low-Density Array study. All the parti-
cipants were recruited for the quantitative RT-PCR assay
in validation of the array data. At the time of enrollment,
each subject was interviewed and examined clinically
and underwent a chest X-ray. Three sputum samples
obtained from each TB patient were analyzed using
the Ziehl-Neelsen stain and Lowenstein-Jensen culture.
Upon admission, all participants were shown to be HIV
negative following examination of the presence of HIV
antibodies in serum samples using an immunodiagnostic
kit for the HIV1/2 antibody (Colloidal Gold; Standard
Diagnostics, Korea). Patients were diagnosed on the
basis of positive results of sputum smear and TB culture,
in combination with clinical symptoms and a chest
X-ray examination. Serum samples were collected from
patients with active TB (N = 30) who had smear-positive
tuberculosis at the time of enrollment and without anti-
TB treatment. Healthy controls were recruited at ran-
dom from people undergoing a regular health check-up.
All had normal appearance in chest X-rays and negative
results of the IFN-γ release assay (IGRA). Healthy con-
trols were free of TB infection, including active and
latent TB infection, and showed no clinical symptoms of
any infectious diseases in the routine check-up. As com-
parisons in array study, 60 serum specimens were col-
lected in parallel from pediatric patients with three other
microbial infections: Bordetella pertussis (BP), varicella-
zoster virus (VZV) and enterovirus (EV). Serum samples
were stored at −80°C within 4 h of collection. This pro-
ject was approved by the Ethics Committee of Jiangsu
Provincial Center for Diseases Prevention and Control
and written informed consent was obtained from all
participants.
RNA extraction
Five serum pools were created (TB group; control group;
three other microbial infection groups (BP, VZV and EV)
by combining 20 samples (20 μl per sample) and mixing
by inversion and 400 μl of each of these pools was used to
extract RNA for assay by TaqMan Low-Density Array
(TLDA). A synthetic Caenorhabditis elegans miRNA
(cel-miR-238 (25 fmol); Takara Biotechnology Co, Dalian,
China) was added into each pooled serum as an internal
control before starting the isolation procedure. Isolation of
total RNA from serum was carried out using mirVana
PARIS kits (Ambion, Austin, TX, USA) following the
instructions provided by the manufacturer with some
modifications. Briefly, the pooled sera were extracted twice
with an equal volume of acid-phenol chloroform and RNA
was eluted with 100 μl Ambion elution solution according
to the instructions provided by the manufacturer. RNA
quantity and purity was measured using a NanoDrop spec-
trophotometer (ND-1000; ThermoScientific, DE, USA).
RNA was extracted from individual serum samples (200 μl)
used for real-time qRT-PCR assays according to a previ-
ously described method [20].
MiRNA profiling using the TaqMan Low-Density Array
MiRNA profiling assays were performed using the TLDA
v2.0 (Applied Biosystems, CA, USA). Each sample was
analyzed with an A & B card for duplicate detection of a
total of 667 miRNAs together with endogenous and
negative controls. Briefly, 50 ng total RNA was added to
4.5 μl reverse transcription (RT) reaction mixture in-
cluding 0.8 μl Megaplex RT Primer Pools A + B (10×),
0.2 μl dNTPs (100 nM), 1.5 μl MultiScribe Reverse
Transcriptase (50 U/μl), 0.8 μl RT Buffer (10×), 0.9 μl
MgCl2 (25 mM), 0.1 μl RNase inhibitor (20 U/μl) and
0.2 μl nuclease-free water. In order to increase the sensi-
tivity of the TLDA, a pre-amplification was performed
after the RT procedure using the TaqMan PreAmp
Mastermix and the Megaplex PreAmp Primer Pools A + B
(Applied Biosystems). All reactions were carried out
according to the protocols recommended by the manufac-
turer. RT products (2.5 μl) were pre-amplified using the
Megaplex PreAmp Primers and reagents. Megaplex RT
reactions were diluted 150-fold with water and 450 μl of
each diluted product was combined with 450 μl TaqMan
2× Universal PCR Master Mix (No AmpErase UNG)
(Applied Biosystems). The sample/master mix for each
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Megaplex pool (100 μl) was loaded into the array,
centrifuged and mechanically sealed with the Applied
Biosystems sealer device. qRT-PCR was carried out on an
Applied Biosystems 7900HT thermocycler using the
cycling conditions recommended by the manufacturer.
Real-time PCR data were analyzed using SDS software
v2.3 (settings: automatic baseline; threshold, 0.2) and rela-
tive miRNA levels were calculated with the RQ Manager
v1.2.1 (Applied Biosystems). Serum miRNA levels were
normalized against cel-miR-238 (spiked-in synthetic
miRNA as an internal control). The threshold cycle (CT)
values over 40 were defined as undetectable.
Candidate miRNA confirmation and quantification by real-
time qRT-PCR
Serum sample miRNA was quantified by TaqMan qRT-
PCR (Applied Biosystems). Assays were performed using
the RT stem-loop primer, PCR primers and probes. RT
reactions were performed using the TaqMan miRNA Re-
verse Transcription Kit and miRNA-specific stem-loop
primers in a scaled down (5 μl) RT reaction containing
1.67 μl RNA. The PCRs were carried out with 10 min
incubation at 95°C followed by 40 cycles of 95°C for 15 s
and 60°C for 1 min in a final volume of 10 μl using a
7900 HT Real-Time PCR System (Applied Biosystems).
A typical reaction consisted of 4.5 μl diluted cDNA
(1:15), 5 μl TaqMan Universal PCR Master Mix (No
AmpErase UNG) and 0.5 μl TaqMan miRNA Assay pri-
mer (Applied BioSystems). Each sample was run in trip-
licate. The CT is defined as the fractional cycle number
at which the fluorescence exceeds the defined threshold.
The data were analyzed with automatic settings for
assigning the baseline. The expression level of miRNA
was normalized to miR-16 [21] and was calculated using
the ΔΔCT method [22].
Target gene analysis
Using TargetScan (www.targetscan.org), the list of genes
predicted to be targeted by the candidated miRNAs were
obtained. The predicted target genes were analyzed for dif-
ferent signaling pathways or functions by NCBI DAVID
server (http://david.abcc.ncifcrf.gov/tools.jsp) with default
setting [23].
Statistical analysis
For qRT-PCR data, the relative expression levels of each
target miRNAs (Log2 relative level) were calculated
according to the difference in CT values between the tar-
get miRNAs and miR-16 (ΔCT). Statistical analysis was
performed with SPSS software version 16.0 (SPSS, Inc.,
Chicago, USA). A P-value <0.05 was considered statisti-
cally significant. For each miRNA, a receiver operating
characteristic (ROC) curve was generated. The area
under curve (AUC) value and 95% confidence intervals
(CI) were calculated to determine the specificity and
sensitivity of TB infection. To increase the diagnostic
accuracy of combined changes in serum miRNA levels,
multiple logistic regression analysis was carried out
according to previously described methods [24].
Results
TB Patient information
The basic demographic characteristics of the participants
are showed in Table 1. A total of 65 participants were
recruited into this study including 30 TB infected
patients (18 men and 12 women; median age, 44.0 ±
14.2 years) and 65 healthy volunteers (35 men and 30
women; median age, 45.3 ± 20.9 years). The 30 active TB
patients were diagnosed on the basis of positive sputum
smear and TB culture results in combination with cli-
nical symptoms and a chest X-ray examination. There
was no significant difference in age and sex distribution
between the TB patients and healthy volunteers.
MiRNA expression profiling of TB infected serum by TLDA
TaqMan Human miRNA Low-Density Array analysis was
performed to identify candidate miRNAs exhibiting altered
levels in response to TB infection. Serum miRNAs from
TB infected patients were compared with those of healthy
controls. Of the 667 miRNAs incorporated in the array,
133 and 166 miRNAs were detected in sera of healthy con-
trols and patients with TB infection, respectively. To iden-
tify TB-specific candidate miRNAs, differential expression
of miRNAs between patients and the healthy controls were
required to meet two criteria: (1) CT values <35 to enable
reliable detection, and (2) miRNA levels exhibiting ≥2-fold
difference between the patient and control groups [25]. A
total of 97 miRNAs met these criteria, 90 of which were
up-regulated and seven were down-regulated in TB
infected patients compared with healthy controls (See
Additional file 1: Table S1 at http://www.biomedcentral.
com). Among these, ten miRNAs (miR-210, miR-432,
miR-423-5p, miR-134, miR-144*, miR-335, miR-26a,
miR-361-5p, miR-889 and miR-576-3p) that were signifi-
cantly up-regulated (≥5 CT difference between the patient
and control groups) were selected for further analysis.
qRT-PCR analysis of miRNA expression in TB infected
serum
The ten candidate miRNAs selected for verification
were confirmed and quantified using qRT-PCR (TaqMan
miRNA Assays). To date, no reliable endogenous control
miRNA has been identified in studying circulating miR-
NAs, although previous studies have implicated miR-16 as
an endogenous control miRNA due to its relatively stable
expression level in sera [21,26]. Therefore, miR-16 was
used as the endogenous control in this study and the
expression levels of candidate miRNAs were normalized
Qi et al. BMC Infectious Diseases 2012, 12:384 Page 3 of 9
http://www.biomedcentral.com/1471-2334/12/384
to miR-16. The expression levels of miR-361-5p, miR-889,
miR-576-3p, miR-210, miR-26a, miR-432, and miR-134
showed significant upregulation in TB infected sera
(P < 0.05), while no significant differences were detected in
the expression of miR-423-5p, miR-335 and miR-144*
(P > 0.05) (Figure 1).
Evaluation of the diagnostic potential of miRNAs for TB
infection
To investigate the characteristics of these miRNAs as
potential diagnostic biomarkers of TB infection, ROC
curve analysis was performed on the miRNAs exhibit-
ing significant differential expression. The ROC curves
of miR-361-5p, miR-889 and miR-576-3p exhibited a
moderate distinguishing efficiency with an AUC value
of 0.848 (95% CI, 0.765-0.932), 0.765 (95% CI,
0.652-0.877) and 0.711 (95% CI, 0.597-0.826), respect-
ively (Figure 2A-C). In multiple logistic regression ana-
lysis of these three differentially expressed miRNAs,
the resulting ROC curve had an AUC value of 0.863
(95% CI 0.778-0.947), which reflects strong separation
between the TB infected and control samples
(Figure 2D). To verify the specificity of the host
miRNAs for TB infection, serum pools from other mi-
crobial infection including (BP, VZV and EV) were also
detected. The data of three miRNAs (miR-361-5p,
miR-889, and miR-576-3p) showed significant differ-
ence between TB and three other microbial infection
groups (Table 2). MicroR-210, miR-26a, miR-432 and
miR-134 showed significant up-regulation in the TB
infected group (P < 0.05), although the AUC was less
than 0.7 (Figure 3), showing poor ability to distinguish
the TB infection. In conclusion, the combination of
miR-361-5p, miR-889 and miR-576-3p was demon-
strated to represent a suitable biomarker that allows
efficient differentiation of TB infections from other
microbial infections.
Target gene prediction
To further investigate the possible function of miR-361-5p,
miR-889 and miR-576-3p, their predicted target genes were
obtained by TargetScan algorithm (239, 509 and 198, re-
spectively). Gene Ontology(GO)analysis showed some
genes targeted by miR-361-5p, miR-889 and miR-576-3p
involved in immune system development (8, 14 and 8 re-
spectively). For example, among predicted genes (SP1,
PGM3, IL10, PIK3R1, RPA1, TGFB2, TGFR1, WEGFA) tar-
geted by miR-361-5p, SP-1 transcription factor (SP1) was a
key signaling pathway for IL-10 expression in the lung [27].
Other genes regulated by miR-361-5p and miR-889 are
associated with respiratory system development (8 and 18)
and lung development (7 and 15).
Discussion
Circulating miRNAs have been extensively investigated
as novel and non-invasive diagnostic and prognostic
markers. Many studies have shown that circulating
miRNAs serve as potential biomarkers for the early de-
tection of different cancers, such as breast cancer [28],
non-small cell lung carcinomas [29,30] and colorectal
cancer [31-33]. More recently, the role of miRNA in
pathogen-host interactions has attracted attention.
Human miRNAs may play important roles in viral repli-
cation, limiting antiviral responses, inhibiting apoptosis
and stimulating cellular growth [34]. MiRNAs are also
associated with immune effects and inflammatory re-
sponse in bacterial infections [35,36]. However, serum/
plasma miRNAs as novel biomarkers for diagnosis of in-
fectious diseases, such as viral or common bacterial
infections, remain to be identified. The diagnosis of M.
tuberculosis infection is more difficult to establish than
almost every other common bacterial infection [37].
Recently, differential miRNA levels as potential biomar-
kers in the diagnosis of TB have been described in per-
ipheral blood mononuclear cells (PBMC) [16-18,38] and
serum [23] from TB patients. For example, Cheng et al.
Table 1 Demographic characteristics of TB patients and healthy controls
Patients group Healthy controls group
Low-Density Array study Validation study Low-Density Array study Validation study
Number of participants 20 30 20 65
Gender (male/female) 10/10 18/12 10/10 35/30
Age (years, mean) 39.2 ± 16.8 44.0 ± 14.2 39.5 ± 16.6 45.3 ± 20.9
Smoking (Yes/no) 4/20 5/30 4/20 10/65
Primary pulmonary lesion by radiography 10 28 0 0
Sputum smear (positive) 20 30 0 0
Culture-positive TB 20 30 NA NA
BCG vaccination (yes/no) 11/5 18/6 20/0 65/0
IGRA-positive TB 20 30 0/20 0/65
HIV - - - -
TB, tuberculosis; BCG, Bacillus Calmette-Guérin vaccine; IGRA, IFN-γ release assay. NA, not applicable; HIV, Human immunodeficiency virus.
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demonstrated that miR-144* was significantly altered in
PBMC from active TB patients [38]. Maertzdorf et al.
showed that miR-361-5p, miR-889, and miR-576-3p
were under-expressed in TB patients [18]. Our studies
demonstrated the potential utility of circulating miRNAs
as diagnostic or prognostic biomarkers of TB infection
by TLDA analysis of miRNAs that were shown to be dif-
ferentially expressed in TB patient sera. The majority of
these showed up-regulated expression while only seven
miRNAs were down-regulated. However, differential ex-
pression of miR-144* was not identified by qRT-PCR in
our study. This discrepancy may be due to the analysis
of different sample types (PBMC and serum). However,
serum is more easily obtained and is regarded as more
stable and therefore represents a preferred sample type
for the analysis of miRNA expression as a circulating
diagnostic biomarker. In comparison with a previously
published data [23], we didn’t observe miR-29a showing
Figure 1 Ten serum miRNA levels in TB patients and healthy controls were selected for verification using real-time qRT-PCR in
individual TB patients (N = 30) and healthy controls (N = 65). Serum levels of miR-361-5p, miR-889, miR-576-3p, miR-210, miR-26a, miR-432
and miR-134 were significantly higher in TB patients compared with those in the control group (**, P < 0.01, * P < 0.05) while no significant
differences were detected in the expression of miR-423-5p, miR-335 and miR-144*. Expression levels of the miRNAs are normalized to miR-16
(Log2 relative level).
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significantly difference in our qRT-PCR results, which
may be attributed to the differences in microarray sys-
tem, sample size, etc.
Tuberculosis is classified as a granulomatous inflam-
matory condition. Macrophages, T lymphocytes, B lym-
phocytes and fibroblasts are among the cells that
aggregate to form granulomas, with lymphocytes sur-
rounding the infected macrophages. All of these cells
secrete miRNAs into the serum. We hypothesized that
serum miRNAs were derived from the release of infected
epithelial cells as well as from other cell types, including
immune cells. The target gene prediction results also
showed the miRNAs might involve in regulation of anti-
TB immunity, respiratory system development and lung
development. Therefore, analysis of a cluster of M tuber-
culosis-associated miRNAs in sera will notably improve
the diagnosis of TB infection although the underlying
mechanism requires further investigation.
Real-time qRT-PCR was performed in individual serum
samples to further verify the ten candidate miRNAs iden-
tified by TLDA. Differential expression of seven miRNAs
(miR-361-5p, miR-889, miR-576-3p, miR-210, miR-26a,
miR-432, and miR-134) was confirmed among these ten
candidate miRNAs. To evaluate the efficiency of these
dysregulated miRNAs for diagnosis of TB infections, ROC
curves were constructed for each miRNA. MiR-361-5p,
miR-889, and miR-576-3p showed good ability to effi-
ciently distinguish TB infections from other microbial
infections, with an AUC value greater than 0.7 in diagnos-
ing TB infection. MiR-361-5p showed greater ability to
distinguish TB infection with an AUC value of 0.848. In
this study, we aimed to increase the diagnosis efficiency of
these markers by using a combination of several host miR-
NAs (miR-361-5p, miR-889, and miR-576-3p). Unfortu-
nately, the efficiency was not significantly improved
although the AUC value increased slightly from 0.848 to
0.863. In order to verify the specificity of the host miRNAs
for TB infection, three different microbial infection serum
Figure 2 Receiver operating characteristic (ROC) curves of differentially expressed miRNAs between TB infected patients and healthy
controls. ROC curves of miR-361-5p (A), miR-889 (B) and miR-576-3p (C) showed a moderate distinguishing efficiency. The combination of miR-
361-5p, miR-889 and miR-576-3p showed a slightly higher AUC value of 0.863 (D).
Table 2 The ΔΔCt value of three miRNAs in TB and
various microbial infections compared with controls
measured by TLDA
miRNA MT/control EV/control VZV/control BP/control
miR-361-5p −5.48 0 0 0
miR-889 −5.05 0 −1.47 −1.82
miR-576-3p −4.51 0 0 0
MT: Mycobacterium tuberculosis; EV: enterovirus; VZV: varicella-zoster virus; BP:
Bordetella pertussis.
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pools (BP, VZV and EV) were also analyzed by TLDA. The
data of three miRNAs (miR-361-5p, miR-889, and
miR-576-3p) showed significant difference between TB
and three other microbial infection groups (Table 2).
Although these three different microbial infection samples
were from children, there was no significant difference of
expression of three miRNAs between adults and children
healthy controls (data not shown). Therefore, miR-361-5p,
miR-889, and miR-576-3p could serve as potential
molecular markers for TB infection.
Previous studies demonstrated that miR-361-5p was
relatively abundant in bleomycin-induced fibrosis in
mouse lungs and that its potential target genes may con-
tribute to the understanding of the molecular mechan-
isms of lung injury and fibrosis [26]. Our studies showed
for the first time that higher levels of miR-361-5p are
expressed in TB patient sera compared with healthy
controls. It can be speculated that this reflects the lung
injury caused by TB infection although the mechanism
remains to be elucidated. Some evidence suggests that
miR-210 can be used as a circulating biomarker for lung
cancer among individuals with CT-detected solitary pul-
monary nodules [39] and miR-26a can be used for diag-
nosis of HBV-related hepatocellular carcinoma [40].
MiR-134 has also been reported as a regulator of cell
proliferation, apoptosis and migration involving lung
septation [41]. Further studies are required to establish
their functions in active TB infection.
Several limitations of our study should be noted. Firstly,
serum miRNA demonstrated only moderate capacity to
differentiate between TB infected patients and controls.
Furthermore, only partially dysregulated miRNAs were
evaluated and other miRNA combinations may provide
more efficient biomarkers. Secondly, our study represents
a preliminary investigation of host responses associated
with different forms of TB infection. Biomarkers are
required for different situations including protection by
vaccination, discrimination of latent and active disease to
facilitate rapid diagnosis and assessment of treatment out-
come and relapse risk [42,43]. Furthermore, additional
investigations conducted in larger numbers of patients
and healthy volunteers are required to validate our
findings.
Conclusions
In summary, TLDA assays revealed dysregulation of 97
miRNAs in active TB patient sera. A combination of
miR-361-5p, miR-889 and miR-576-3p was identified as
Figure 3 Receiver operating characteristic (ROC) curves of differentially expressed miRNAs between TB infected patients and healthy
controls. ROC curves of miR-210 (A), miR-26a (B), miR-432 (C) and miR-134 (D) yielded an AUC value less than 0.7.
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a potential non-invasive molecular marker for rapid
diagnosis of TB infection. The biological mechanism of
the dysregulation in these miRNAs and their therapeutic
potential in TB infections require further investigation.
Additional file
Additional file 1: Table S1. Differential expressed miRNAs in TB
infected patients compared with controls.
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